Hyperphenylalaninaemia (HPA) is an inherited disorder that results in raised plasma phenylalanine levels with a range of severities, including phenylketonuria (PKU). Since the first attempts at treatment using a low-phenylalanine diet and after more than 50 years of research, considerable progress has been made so we are now at a stage where mental retardation caused by high plasma phenylalanine can be prevented. We must, however, be aware of the new challenges we face in managing PKU. These include: maintaining optimal growth by providing enough phenylalanine without jeopardizing the child's psychomotor development; providing an optimal nutritional status that ensures other essential nutrients, such as long chain polyunsaturated fatty acids, are not excluded from the diet; ensuring optimal compliance to the dietary intervention; and considering patients' quality of life. New strategies, such as tetrahydrobiopterin (BH4) supplementation, need to be evaluated with regard to safety, efficacy and expected outcomes in specific types of HPA.
ScriverCRKaufmanSEisensmithRC: The hyperphenylalaninemias. In: The Metabolic and Molecular Bases of Inherited Disease, 7th edn (ScriverCRBeaudetALSlyWS, eds). New York: McGraw-Hill, 1995; pp 1015–1075.
2.
GuttlerFGuldbergP: The influence of mutations on enzyme activity and phenylalanine tolerance in phenylalanine hydroxylase deficiency. Eur J Pediatr1996; 155 (suppl 1): S6–10.
3.
BickUFarhendorfGLudolphAG: Disturbed myelination in patients with treated hyperphenylalaninemias: Evaluation with magnetic resonance imaging. Eur J Pediatr1999; 150: 185–189.
4.
KorinthenbergRUllrichKFullenkemperF: Evoked potentials and electroencephalography in adolescents with phenylketonuria. Neuropediatrics1988; 19: 175–178.
5.
Medical Research Council Working Party on Phenylketonuria: Phenylketonuria due to phenylalanine hydroxylase deficiency: An unfolding story. BMJ1993; 306: 115–119.
6.
AcostaPBStepnick-GropperS: Problems related to diet management of maternal phenylketonuria. J Inher Metab Dis1986; 9: 183–201.
7.
AgostoniCRivaEValsasinaR: Plasma and urine levels of taurine in PKU children and in a normal control population. Fifth International Congress of Inborn Errors of Metabolism, Asilomar, Pacific Grove, CA, 1990. Abstract OC6.2.
8.
SchulpisKHNamopoulosCScarpalezouA: Serum carnitine level in phenylketonuria children under dietary control in Greece. Acta Paediatr Scand1990; 79: 930–934.
WeglageJPietschMFundersB: Neurological findings in early treated phenylketonuria. Acta Paediatr1995; 84: 411–415.
11.
National Institutes of Health Consensus Development Panel: National Institutes of Health Consensus Development Conference Statement: Phenylketonuria: Screening and management, October 16–18, 2000. Pediatrics2001108: 972–982.
12.
RivaEAgostoniCBiasucciG: Early breastfeeding is linked to higher intelligence quotient score in dietary treated phenylketonuric children. Acta Paediatr1996; 85: 56–58.
13.
RaihaNCR: Milk protein quantity and quality and protein requirements during development. Adv Pediatr1989; 36: 347–348.
14.
HorrocksLAYeoYK: Health benefits of docosahexaenoic acid (DHA). Pharmacol Res1999; 40: 211–225.
LantingCIFidlerVHuismanM: Neurological differences between 9-years-old children fed breast-milk or formula-milk as babies. Lancet1994; 344: 1319–1322.
17.
MakridesMNeumannMAByardRW: Fatty acid composition of brain, retina, and erythrocytes in breast- and formula-fed infants. Am J Clin Nutr1994; 60: 189–194.
18.
FarquharsonJJamiesonECAbbasiKA: Effect of diet on the fatty acid composition of major phospholipids of infant cerebral cortex. Arch Dis Child1995; 72: 198–203.
19.
CockburnFClarkBJCaineEA: Fatty acids in the stability of the neuronal membrane: Relevance to PKU. Int Pediatr1996; 11: 56–60.
20.
AgostoniCHarvieAMcCullochDL: A randomised trial of long-chain polyunsaturated fatty acid supplementation in infants with phenylketonuria. Dev Med Child Neurol2006; 48: 207–212.
21.
MalcolmCAHamiltonRHMcCullochDL: Maternal docosahexaenoic acid supplementation during pregnancy and visual evoked potential development in term infants: A double blind, prospective randomized trial. Arch Dis Child Fetal Neonatal Ed2003; 88: F383–F390.
22.
GalliCAgostoniCMosconiC: Reduced plasma C-20 and C-22 polyunsaturated fatty acids in children with phenylketonuria during dietary intervention. J Pediatr1991; 119: 562–567.
23.
AgostoniCVerduciEMassettoN: Long terms effects of long chain polyunsaturated fats in hyperphenylalaninemic children. Arch Dis Child2003; 88: 582–583.
24.
AcostaPBYannicelliSSinghR: Nutrient intakes and physical growth of children with phenylketonuria undergoing nutrition therapy. J Am Diet Assoc2003; 103: 1167–1173.
25.
Rolland-CacheraMFDeheegerMBellisleF: Adiposity rebound in children: A simple indicator for predicting obesity. Am J Clin Nutr1984; 39: 129–135.
26.
McBurnieMAKronmalRAKochR: Physical growth of children treated for phenylketonuria. Ann Hum Biol1991; 18: 357–368.
27.
ScaglioniSVerduciEFioriL: Body mass index rebound and overweight at 8 years of age in hyperphenylalaninemic children. Acta Paediatr2004; 93: 1596–1600.
28.
ChristensenHN: Metabolism of amino acids and proteins. Annu Rev Biochem1953; 22: 233–260.
29.
PietzJKreisRRuppA: Large neutral amino acids block phenylketonuria transport into brain tissue in patients with phenylketonuria. J Clin Invest1999; 103: 1169–1178.
30.
KochRMoseleyKDYanoS: Large neutral amino acid therapy and phenylketonuria: A promising approach to treatment. Mol Genet Metab2003; 79: 110–113.
31.
TrefzFKAulela-ScholzCBlauN: Successful treatment of phenylketonuria with tetrahydrobiopterin. Eur J Pediatr2001; 160: 315.
32.
FiegeBBonaféLBallhausenD: Extended tetrahydrobiopterin loading test in the diagnosis of cofactor-responsive phenylketonuria: A pilot study. Mol Genet Metab2005; 86: S91–S95.
33.
FioriLFiegeBRivaE: Incidence of BH4-responsiveness in phenylalanine-hydroxylase-deficient Italian patients. Mol Genet Metab2005; 86: S67–S74.
